Coverage
-
January 14, 2022
The full Federal Circuit said Friday that it will not review a panel decision wiping out Bristol-Myers Squibb subsidiary Juno Therapeutics' $1.2 billion patent infringement victory against Gilead's Kite Pharma Inc.
10 other articles on this case.
View all »